ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025
Elevated levels of cerebrospinal fluid CHIT1 correlate with disease activity in neuromyelitis optica spectrum disorder.
Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundNeuromyelitis optica spectrum disorder (NMOSD) is a severe autoimmune inflammatory disease of the central nervous system characterized by microglial activation and neuroinflammation. Chitotriosidase (CHIT1), a microglial activation biomarker, has been implicated in neurodegenerative and neuroinflammatory diseases, but its role in NMOSD remains unclear.
methodsThirty-four patients with NMOSD, 30 healthy controls (HCs), and 30 patients with other noninflammatory neurological disorders (ONNDs) were included. Cerebrospinal fluid (CSF) and serum CHIT1 levels were measured via enzyme-linked immunosorbent assay. Comprehensive clinical parameters were collected from all participants. Statistical comparisons and receiver operating characteristic (ROC) curve analyses were performed to evaluate the diagnostic performance of CHIT1 for NMOSD.
resultsCSF CHIT1 levels were significantly higher in the NMOSD group than in the ONND group (p < 0.001). In contrast, serum CHIT1 levels did not differ significantly between NMOSD patients and either ONND or HC groups. Subgroup analysis revealed higher CSF CHIT1 concentrations in NMOSD patients with gadolinium-enhancing lesions than in those without such lesions (p = 0.035). ROC analysis demonstrated that CSF CHIT1 could distinguish NMOSD patients from patients with ONNDs, with an area under the curve of 0.730. Additionally, CSF CHIT1 levels correlated positively with the Expanded Disability Status Scale score (r = 0.457, p = 0.007).
conclusionAn elevated CSF CHIT1 level in NMOSD patients is significantly associated with greater disease severity, suggesting its potential as a diagnostic and prognostic biomarker. These findings highlight the role of CHIT1 in the pathogenesis of NMOSD and warrant further investigation into its clinical applicability.
Indexed as
Identifiers
41037213What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.